



PATENT APPLICATION

Our File No.: 20040873.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Adrian Hill et al : February 25, 2005
S.N. : 10/511,415 : Art Unit Unknown
Filed : October 14, 2004
For : METHODS OF TREATMENT AND DIAGNOSIS OF
PATIENTS WITH HEPATITIS C INFECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- ☐ 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- ☐ 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in § 1.491 in the international application. No fee is required.
- ☒ 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- ☐ 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a

final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- [] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- [] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or
- [] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.
- [] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.
- [] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the

above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: February 25, 2005.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.




C. G. Mersereau
Attorney for Applicant(s)
Registration No. 26,205
900 Second Avenue South
Suite 820
Minneapolis, MN 55402
Phone: 612-339-7461




CERTIFICATE OF MAILING

I hereby certify that the foregoing Supplemental Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/511,415 of inventors, Adrian Hill et al, filed October 14, 2004, for "METHODS OF TREATMENT AND DIAGNOSIS OF PATIENTS WITH HEPATITIS C INFECTION" are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 25, 2005.



Barbara L. Davis
Secretary to C. G. Mersereau

Date of Signature: February 25, 2005

(2-92)
Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Document Number 20040873.ORI	Application Number 10/511,415
	Applicant Adrian Hill et al	
	Filing Date October 14, 2004	Group Art Unit Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Bismuth et al, CLINICAL TRANSPLANTS, <i>The Paul Brousse Liver Transplant Series 1989 to 1992: New Trends in the Last Four Years</i> , 1992, pp. 161-166
	Sen et al, NATURE, <i>Interferon, Double-Stranded RNA and mRNA Degradation</i> , Vol. 264, November 25, 1976, pp. 370-373
	Silverman et al, EUROPEAN JOURNAL OF BIOCHEMISTRY, <i>Control of the ppp(A2'p)_nA System in HeLa Cells, Effects of Interferon and Virus Infection</i> , Vol. 124, 1982, pp. 131-138
	Solinas et al, LIVER, <i>Changes of Serum 2',5'-oligoadenylate Synthetase Activity During Interferon Treatment of chronic Hepatitis C</i> , Vol. 13, 1993, pp. 253-258
	Torrence et al, ANALYTICAL BIOCHEMISTRY, <i>Assay of 2',5'-Oligoadenylate Phosphodiesterase Activity in Mouse L-Cell Extracts</i> , Vol. 129, 1983, pp. 103-110
	Xu et al, JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, <i>Genomic Features of Human PKR: Alternative Splicing and a Polymorphic CGG Repeat in the 5'-Untranslated Region</i> , Vol. 18, 1998, pp. 609-616
	McMillan al, PROTEIN PHOSPHORYLATION IN CELL GROWTH REGULATION; LONDON, HARWOOD, <i>Structure and Function of the Interferon-Induced Protein Kinase PKR and Related Enzymes</i> , 1996, pp. 225-253

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.